Stress hyperglycemia is predictive of clinical outcomes in patients with spontaneous intracerebral hemorrhage.
Glucose-to-HbA1c ratio
Intracerebral hemorrhage
Prognosis
Stress hyperglycemia
Journal
BMC neurology
ISSN: 1471-2377
Titre abrégé: BMC Neurol
Pays: England
ID NLM: 100968555
Informations de publication
Date de publication:
27 Jun 2022
27 Jun 2022
Historique:
received:
31
01
2022
accepted:
20
06
2022
entrez:
27
6
2022
pubmed:
28
6
2022
medline:
30
6
2022
Statut:
epublish
Résumé
Stress hyperglycemia is a common condition in patients suffering from critical illness such as spontaneous intracerebral hemorrhage (ICH). Our study aimed to use glucose-to-glycated hemoglobin (HbA1c) ratio to investigate the impact of stress hyperglycemia on clinical outcomes in patients with ICH. A sample of eligible 586 patients with spontaneous intracerebral hemorrhage from a multicenter, hospital-based cohort between 2014 and 2016 were recruited in our study. Stress hyperglycemia was evaluated by the index of the glucose-to-HbA1c ratio that was calculated by fasting blood glucose (mmol/L) divided by HbA1c (%). Patients were divided into two groups based on the median of the glucose-to-HbA1c ratio. The main outcomes were poor functional outcomes (modified Rankin Scale score of 3-6) at discharge and 90 days. Multivariable logistic regression and stratified analyses were performed to explore the association of stress hyperglycemia with poor prognosis of ICH. On multivariable analysis, higher glucose-to-HbA1c ratio (≥1.02) was independently correlated with poor functional outcomes at discharge (adjusted OR = 3.52, 95%CI: 1.98-6.23) and 90 days (adjusted OR = 2.27, 95%CI: 1.38-3.73) after adjusting for potential confounding factors. The correlation between glucose-to-HbA1c ratio and worse functional outcomes still retained in patients with or without diabetes mellitus. Stress hyperglycemia, calculated by glucose-to-HbA1c ratio, was independently correlated with worse functional outcomes at discharge and 90 days in patients with ICH. Moreover, glucose-to-HbA1c ratio, might not only be used as a simple and readily available index to predict clinical outcomes of ICH but also provide meaningful insight into future analysis to investigate the optimal range of glucose levels among ICH patients and develop tailored glucose-lowering strategies.
Sections du résumé
BACKGROUND
BACKGROUND
Stress hyperglycemia is a common condition in patients suffering from critical illness such as spontaneous intracerebral hemorrhage (ICH). Our study aimed to use glucose-to-glycated hemoglobin (HbA1c) ratio to investigate the impact of stress hyperglycemia on clinical outcomes in patients with ICH.
METHODS
METHODS
A sample of eligible 586 patients with spontaneous intracerebral hemorrhage from a multicenter, hospital-based cohort between 2014 and 2016 were recruited in our study. Stress hyperglycemia was evaluated by the index of the glucose-to-HbA1c ratio that was calculated by fasting blood glucose (mmol/L) divided by HbA1c (%). Patients were divided into two groups based on the median of the glucose-to-HbA1c ratio. The main outcomes were poor functional outcomes (modified Rankin Scale score of 3-6) at discharge and 90 days. Multivariable logistic regression and stratified analyses were performed to explore the association of stress hyperglycemia with poor prognosis of ICH.
RESULTS
RESULTS
On multivariable analysis, higher glucose-to-HbA1c ratio (≥1.02) was independently correlated with poor functional outcomes at discharge (adjusted OR = 3.52, 95%CI: 1.98-6.23) and 90 days (adjusted OR = 2.27, 95%CI: 1.38-3.73) after adjusting for potential confounding factors. The correlation between glucose-to-HbA1c ratio and worse functional outcomes still retained in patients with or without diabetes mellitus.
CONCLUSIONS
CONCLUSIONS
Stress hyperglycemia, calculated by glucose-to-HbA1c ratio, was independently correlated with worse functional outcomes at discharge and 90 days in patients with ICH. Moreover, glucose-to-HbA1c ratio, might not only be used as a simple and readily available index to predict clinical outcomes of ICH but also provide meaningful insight into future analysis to investigate the optimal range of glucose levels among ICH patients and develop tailored glucose-lowering strategies.
Identifiants
pubmed: 35761206
doi: 10.1186/s12883-022-02760-9
pii: 10.1186/s12883-022-02760-9
pmc: PMC9235136
doi:
Substances chimiques
Blood Glucose
0
Glycated Hemoglobin A
0
Types de publication
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
236Informations de copyright
© 2022. The Author(s).
Références
World Neurosurg. 2018 Jun;114:e756-e765
pubmed: 29555604
Stroke. 2015 Jul;46(7):2032-60
pubmed: 26022637
J Stroke Cerebrovasc Dis. 2019 Jan;28(1):213-219
pubmed: 30539756
Front Neurosci. 2018 Jun 19;12:414
pubmed: 29970985
Neurology. 2017 Mar 7;88(10):985-990
pubmed: 28159886
Stroke. 2013 Jun;44(6):1682-9
pubmed: 23592763
Nat Med. 2011 Feb;17(2):206-10
pubmed: 21258336
Stroke. 2016 Mar;47(3):682-8
pubmed: 26814235
Am J Kidney Dis. 2011 Jul;58(1):56-63
pubmed: 21601325
Front Neurol. 2019 Sep 18;10:1003
pubmed: 31620074
J Stroke Cerebrovasc Dis. 2019 Jun;28(6):1668-1673
pubmed: 30890395
Diabetes Metab. 2017 Feb;43(1):40-47
pubmed: 27663631
J Neurosurg. 2009 Mar;110(3):411-7
pubmed: 19249937
J Cereb Blood Flow Metab. 1992 May;12(3):469-76
pubmed: 1569140
Clin Interv Aging. 2021 Mar 09;16:431-442
pubmed: 33727806
Neurology. 2003 Nov 25;61(10):1351-6
pubmed: 14638954
QJM. 2022 Jan 21;115(1):7-11
pubmed: 32810234
Stroke. 2006 Jan;37(1):199-203
pubmed: 16339481
Front Neurol. 2020 Sep 24;11:576895
pubmed: 33071954
J Pak Med Assoc. 2010 Aug;60(8):660-3
pubmed: 20726199
Lancet Neurol. 2012 Aug;11(8):720-31
pubmed: 22698888
Neurocrit Care. 2010 Aug;13(1):67-74
pubmed: 20390379
Lancet Neurol. 2009 Apr;8(4):355-69
pubmed: 19233729
Lancet Neurol. 2019 Apr;18(4):394-405
pubmed: 30878104
Crit Care. 2013 Mar 06;17(2):305
pubmed: 23470218
J Clin Endocrinol Metab. 2015 Dec;100(12):4490-7
pubmed: 26485219
J Thromb Thrombolysis. 2021 Apr;51(3):789-797
pubmed: 32830310
Mol Neurobiol. 2016 May;53(4):2269-75
pubmed: 25972238
Front Aging Neurosci. 2022 Feb 08;14:782282
pubmed: 35211004
Neurocrit Care. 2020 Apr;32(2):427-436
pubmed: 31313140
Stroke. 2001 Oct;32(10):2426-32
pubmed: 11588337
Front Neurol. 2022 Jan 13;12:785428
pubmed: 35095730
Int J Stroke. 2014 Oct;9(7):840-55
pubmed: 25156220
Diabetes Care. 2018 Jan;41(Suppl 1):S13-S27
pubmed: 29222373
Int J Chron Obstruct Pulmon Dis. 2017 Jul 03;12:1923-1932
pubmed: 28740373
Sci Rep. 2019 Apr 18;9(1):6279
pubmed: 31000758
Miner Electrolyte Metab. 1997;23(3-6):253-60
pubmed: 9387128
Stroke. 2022 Apr;53(4):1226-1234
pubmed: 34844422
Sci Rep. 2019 Dec 13;9(1):19054
pubmed: 31836800
Stroke. 1996 Aug;27(8):1304-5
pubmed: 8711791
JAMA. 2014 Mar 26;311(12):1225-33
pubmed: 24668104
Lancet. 2009 May 23;373(9677):1798-807
pubmed: 19465235
Lancet Neurol. 2010 Feb;9(2):167-76
pubmed: 20056489
Int J Cardiol. 2017 Aug 15;241:57-63
pubmed: 28256326
Diabetes Care. 2020 Feb;43(2):440-445
pubmed: 31852727
J Neurol Sci. 2007 Apr 15;255(1-2):90-4
pubmed: 17350046
Eur J Neurol. 2016 Nov;23(11):1658-1665
pubmed: 27444813
J Neurol Neurosurg Psychiatry. 2008 Dec;79(12):1382-5
pubmed: 18403438
Neurol Res. 2017 Feb;39(2):152-157
pubmed: 28019142
J Cereb Blood Flow Metab. 1985 Jun;5(2):253-8
pubmed: 3988824
Stroke. 2012 Jan;43(1):243-5
pubmed: 21940959